Salix Pharmaceuticals Ltd. (SLXP) posted a third quarter loss of $7.3 million or $0.15 per share, compared to a loss of $5.4 million or $0.11 per share in the prior year period.
On average, nine analysts polled by Thomson Reuters expected the company to report a loss of $0.29 per share. Analysts' estimates typically exclude special items.
Total product revenue for the quarter was $65.7 million, compared to $42.9 million in last year period. Nine Wall Street analysts expected revenues of $60.42 million.
Looking forward, for the fourth quarter, the company expects product revenue to be approximately $68 million and a loss of approximately $0.14 per share.
Street analysts expect a loss of $0.03 per share on revenues of $72.28 million.
Further ahead, for the fiscal year 2009, the company expects total product revenue to be approximately $230 million, and a loss of approximately $0.90 per share.
Street analysts expect a loss of $0.92 per share on revenues of $230.18 million.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.